Phase 2 Cardiomyopathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 40 and 80 years old.
• People who have heart failure with a weakened heart pump (where the heart is pumping less blood than normal), caused either by blocked arteries or other reasons, confirmed by a heart scan showing the pumping function is below 40%.
• People who have a heart condition caused by a protein build-up called ATTR cardiomyopathy, with any level of heart pumping function confirmed by a heart scan.
• People whose heart failure medicines have been stable and at the best tolerated doses for at least 3 months, with no changes to their treatment for at least 1 month.
• People with a specific blood marker level (NT-proBNP) above a certain threshold — above 125 pg/mL for those under 75 years old, or above 450 pg/mL for those 75 and older.

Who may not be able to join:

• People who have had a heart procedure (such as a stent or bypass) in the past 3 months.
• People who are pregnant.
• People who have endometriosis (a condition where tissue similar to the uterine lining grows outside the uterus).
• People who have uterine fibroids (non-cancerous growths in the uterus).
• People with a current cancer diagnosis, including breast cancer, an abnormal mammogram result, a family history of cancer, or who carry the BRCA1 or BRCA2 gene variants.
• People who follow a vegan diet.
• People who take supplements such as isoflavonoids, genistein, or resveratrol.
• People with alcohol use concerns — for men, this means drinking more than 4 drinks on any single day or more than 14 drinks per week; for women, more than 3 drinks on any single day or more than 7 drinks per week.
• People with liver problems, where certain liver function blood test results are significantly above the normal range (confirm specific values with the trial site).
• People currently taking hormone replacement therapy (HRT).
• People currently taking thyroid supplements.
• People with significantly reduced kidney function (eGFR below 25 mL/min/1.73 m²) (confirm with trial site).
• People with poorly controlled diabetes, where a blood sugar marker (HbA1c) is above 10%.
• People with blood clotting disorders.
• People with certain low blood cell counts, including low white blood cells, haemoglobin below 9 mg/dL, or low platelets.
• People who have been hospitalised in the past 3 months for any reason other than heart failure.
• People whose heart failure symptoms fall into the mildest category (no symptoms at all) or the most severe category (symptoms even at rest), based on a standard heart failure classification system.
• People with an active bacterial or viral infection, or a flare-up of a long-term infection.
• People with a known allergy to genistein or inulin.
• People with a known allergy to perflutren dye, which is used in certain heart ultrasound scans.

Important: Always verify eligibility with the trial site directly before applying.